A Globally Rising Burden of Sexually Transmitted Diseases (STDs)

Womens Health

GI Dynamics’s I-STEP Clinical Study of EndoBarr...

First Patient Enrolled in I-STEP Clinical Study of EndoBarrier in India On February 13, 2023, GI Dynamics Inc., a medical device company, announced the enrollment of the first candidate in the I-ST...

Feb 16, 2023

Aesthetic Implants Market Outlook , Key Trends and Developments
Aesthetic Implants Market : Evaluating the Major Factors Creating the Demand for Aesthetic Products

The idea of aesthetic implants or cosmetic surgery has always been a topic of conversation and debate in the healthcare market. Despite that, the demand for aesthetic implants has grown several folds over the past few years, especially among the younger generation, to enhance their physical appearance and to look m...

Find More
at-home medical equipment and devices
How At-Home Medical Equipment is Improving the Quality of Medical Care?

An essential fact of today's healthcare system is that patients are released from hospitals due to increased stress even when they still need care. As a result, both the patient and professional caregivers utilize various technologies, including some complex mechanisms, in noninstitutional settings to manage their ...

Find More
Pharma News for CG Oncology, Amgen, Elevar, and GSK
CG Oncology Teams Up With Merck & BMS; Parse Biosciences Partners With Molecular Diagnostics Korea; Amgen’s Olpasiran; Elevar Therapeutics Announces Results of Rivoceranib; FDA Approves GSK’s Measles Vaccine; Sage & Biogen Reveals Postpartum Depression Trial Result

FDA Gives Green Signal to First Measles Vaccine in Almost 50 Years GSK announced that the company's vaccine for protection against mumps, measles, and rubella (MMR) had been approved by the U.S. FDA. According to data from six clinical studies, the company filed a Biologics License Application in August 2021. ...

Find More

More Views & Analysis

pharma-news-for-noxxon-nuvalent-stryker-exact-sciences
Noxxon’s NOX-A12 clinical trial; Exact Sciences buys PreventionGenetics; Nuvalent’s clinical trails for NVL-520; Stryker acquires Vocera Communications

Noxxon continues enrolment in a glioblastoma therapy trial Noxxon Pharma continues subject enrolment in the GLORIA clinical trial of NOX-A12 in brain cancer (glioblastoma) patients. The move comes after the Data Safety Monitoring Board (DSMB) evaluated safety results from the preliminary four-week treatment with...

Find More

femtech-market
FemTech Market: With 100+ Startups in the domain, Women Healthcare is Witnessing a Huge Upliftment

Gender disparity is not new to ears. To look at all the corners, women have been and are still affected due to financial vulnerability, unequal access to education, and disproportionate facilities; and Healthcare is no immune to this fallout. Female infanticide, malignant neglect of women's sexual- and reproductive...

Find More

global-burden-of-sexually-transmitted-diseases-std
A Globally Rising Burden of Sexually Transmitted Diseases (STDs)

Caused by bacteria, viruses, and parasites, Sexually transmitted diseases (STDs) are a global health burden and it seems they are likely to maintain their status of being so in coming years also, primarily due to the lack of knowledge, and awareness. Further, diagnostics and screening, poverty, the stigma associate...

Find More

latest pharma news
AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid’s DMD gene therapy trial

AZ, Daiichi put their trust into TROP2-based drugs, inks an oncology deal to together develop and commercialize DS-1062 AstraZeneca has inked an oncology deal with Daiichi Sankyo to jointly develop and commercialize an antibody-drug conjugate DS-1062 (trastuzumab deruxtecan), worldwide except in Japan. Daiichi ...

Find More

recent-pharma-news-and-update
Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai’s Collaboration; A new study on averting heart attack

Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas.   The capital will bankroll a phase 1/2 study of the asset, OP-1250, as a single agent. Olema Oncology will a...

Find More

latest-pharma-news-and-updates
Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update

Orchard licenses the gene therapy technology from GlaxoSmithKline  Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for its use in hematopoietic stem cell gene therapies. GSK filed for patents on the tech before selling its rare disease gene therapy portfolio to...

Find More

Myocardial Infarction
Myocardial Infarction...

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More
Acute Ischemic Stroke (AIS)
Acute Ischemic Stroke (AI...

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More
Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More